“This will give us another excellent treatment opportunity for our patients,” says Daniel Aletaha, head of the rheumatology division. “We will soon have another option for patients who do not respond to the first therapy or subsequent therapies,” he said.
Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.
